Merck: Phase 3 trials abandoned
(CercleFinance.com) - Merck has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody for lung cancer.
Vibostolimab is being evaluated as an experimental fixed-dose combination with pembrolizumab (KEYTRUDA) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
Merck is discontinuing the KeyVibe-003 and KeyVibe-007 phase 3 trials evaluating the fixed-dose combination of vibostolimab and pembrolizumab in selected patients with non-small cell lung cancer (NSCLC), on the recommendation of an independent Data Monitoring Committee (DMC).
In view of the overall data from the KeyVibe phase 3 studies, including the efficacy results of KeyVibe-003 and KeyVibe-007, the company has decided to discontinue the KeyVibe-006 phase 3 trial and other vibostolimab studies.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Vibostolimab is being evaluated as an experimental fixed-dose combination with pembrolizumab (KEYTRUDA) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
Merck is discontinuing the KeyVibe-003 and KeyVibe-007 phase 3 trials evaluating the fixed-dose combination of vibostolimab and pembrolizumab in selected patients with non-small cell lung cancer (NSCLC), on the recommendation of an independent Data Monitoring Committee (DMC).
In view of the overall data from the KeyVibe phase 3 studies, including the efficacy results of KeyVibe-003 and KeyVibe-007, the company has decided to discontinue the KeyVibe-006 phase 3 trial and other vibostolimab studies.
Copyright (c) 2024 CercleFinance.com. All rights reserved.